WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206494
Description: EPI-506 is a potent and selective NTD inhibitor (inhibitor of the androgen receptor (AR) N-terminal domain (NTD)). In vitro and in vivo studies have shown activity against full length AR and constitutively active AR splice variants, including AR-V7 (associated with resistance to abiraterone and enzalutamide). EPI-506 is expected to be effective in mCRPC driven by both canonical and aberrant AR signaling by targeting the NTD common to full length and splice variant AR. EPI-506 is the first agent with the potential to inhibit both canonical and variant-mediated AR signaling.
MedKoo Cat#: 206494
EPI-506 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: EPI-506; EPI 506; EPI506.
IUPAC/Chemical Name: Unknown
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Maughan BL, Antonarakis ES. Clinical Relevance of Androgen Receptor Splice
Variants in Castration-Resistant Prostate Cancer. Curr Treat Options Oncol. 2015
Dec;16(12):57. doi: 10.1007/s11864-015-0375-z. PubMed PMID: 26537882.